Viridian Therapeutics reports positive Phase 1 results for VRDN-008
VRDN•Viridian Therapeutics reported positive Phase 1 results for VRDN-008, including a 15–18-day half-life, 74% peak IgG reduction through eight weeks and a favorable safety profile. The company plans to initiate at least one pivotal clinical trial in 2027.
1. Phase 1 results
Viridian Therapeutics said VRDN-008 demonstrated a 15–18-day half-life, 74% peak IgG reduction through eight weeks and a favorable safety profile in a Phase 1 trial. The company plans to initiate at least one pivotal clinical trial in 2027.
